Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B

2015 Annals of Hepatology 14;6 (826-836)

BACKGROUND & AIMS: A novel controlled attenuation parameter (CAP) using the signals acquired by the FibroScan(R) has been developed as a method for evaluating steatosis. The aim of this study is to assess the performance of the CAP for the detection and quantification of steatosis in patients with chronic hepatitis B (CHB). MATERIAL AND METHODS: 136 subjects with CHB underwent liver biopsy and FibroScan(R) within 60 days. CAP was evaluated retrospectively using raw FibroScan(R) data. Steatosis was graded as follows: S0 (steatosis /= 60%). Performance was evaluated by area under the receiver operating characteristic (AUROC) curve. RESULTS: Proportions of each steatosis grade (S0-S3) were 78, 10, 9 and 3%, respectively. Using univariate analysis, liver stiffness measurement (LMS) significantly correlated with fibrosis (tau = 0.43; P /= 2, F >/= 3 and F = 4. AUROCs for CAP were: 0.82 (0.73-0.92), 0.82 (0.69-0.95), and 0.97 (0.84-1.00) for >/= S1, >/= S2 and S3 steatosis, respectively. CONCLUSIONS: In conclusion CAP is a novel, accurate non-invasive tool and may be suitable for detecting and quantifying steatosis in CHB patients.

Pubmed : 26436354